Can machine learning help bDMARD selection in RA? Early days limited by the data available, so not great yet, but efforts underway are a good start for an area where we need to do better than our status quo guessing. Watch this space POS0641 #EULAR2023 @RheumNow https://t.co/2j8H40iFWo

TNFi & Disease activity-guided dose optimization in RA⬇️prog of ADA or ETA daily dose (100%66%50%0%) 10yrs followup in 170pts ⭐️74% tapered until full discontinuation ⭐️Median time to restart 8 mo ⭐️21% never restarted! What's lacking? % of recovery @Rheumnow OP0131 #EULAR23 https://t.co/Ms6lqQ7cWf

Rituximab in RA - do you need to maintain B cell depletion? Well, in this Paris cohort, if you divide up patients by B cell depletion (at time of next infusion) - no diff in efficacy. Bias possible but B cell depletion in RA isn’t the hill to die on POS0636 #EULAR2023 @RheumNow https://t.co/GLdu9YkL7g

CareRA trial: 3 months addition of LEF vs. ETA in pts resistant to COBRA-Slim regimen (MTX 15 mg/w + step-down prednisone): After 2 years, no difference in dis control but those who received ETA early were treated more frequently w/ csDMARD monotherapy #EULAR23 @RheumNow OP0129 https://t.co/YwSoZWi375

Don’t be ‘rash’, get adult immune compromised Pts vaccinated against #shingles #varicella #zoster K Winthrop has research re #HZ #vaccination with #Shingrix in #Upadacitinib at #EULAR2023 #OP0225 Bottom line-get #immunecompromised Pts with #rheumatoidarthritis jabbed! @RheumNow

“You don’t need MTX with TCZ for RA” Err, well: - just like TNFi, you def can get ADAb to TCZ - they definitely lead to lower response rates - MTX co-admin reduces ADAb Seems like a good idea to me, but your call 🤷‍♂️ Bitoun, Mariette et al POS0630 #EULAR2023 @RheumNow https://t.co/2jOAqA6YZ3

The risk of demyelination with TNFi is low but real. Slight increase of risk was found in male RA patients. The small number of events is reassuring. Careful consideration is recommended in individuals at highest risk of demyelinating diseases Abst#OP0135 #EULAR2023 @RheumNow https://t.co/YT6ZrJTjU0

In polyrefractory RA patients, half did not have any PDUS change on ultrasound and/or had normal CRP levels, showing that in the other half, new mechanisms of action for treatment is required by David P, Abst#OP0134 ##EULAR2023 @RheumNow https://t.co/TaY7uGU0bg

No relationship between MTX-PG levels in terms of efficacy by SDAI remission but higher MTX-PG levels related to adverse events by Tamai H, Abstr #OP0128 #EULAR2023 @RheumNow https://t.co/TiO5eeYlnS

We’re getting better at understanding different types of refractory RA (D2T RA) We see differences with refractory RA subtypes: PIRRA (persistently inflamm on USS), and NIRRA (non-inflamm) hopefully moving to data-driven Rx approaches for D2T RA? OP0134 #EULAR2023 @RheumNow https://t.co/vX5IK5O9Wm

Difficult to treat #rheumatoid #arthritis is a grab bag of multi drug failures or intolerant with high or LOW disease activity 3 groups and diff reasons for failure and diff risk factors. ? Sunset the D2T Pts? OP0117 #EULAR2023 @RheumNow @eular_org https://t.co/1qPMq32kVz

The overall risk of cancer and cardiovascular disease were decreased in RA treated with JAKi but there was no comparison with TNFi, Sung Soo Ahn, Abst#00132 #EULAR2023 @RheumNow https://t.co/9Bi6t6uuig

Biologic dose reduction based on disease activity resulted in 40% reduction in TNFi and did not seem to cause disease deterioration from the 10 year DRESS Study by N van Herwaarden, Abst#OP00131 #EULAR2023 @RheumNow https://t.co/ncGPF9ODcF

Abatacept use in individuals at risk of RA reduced the rate of progression to RA during the treatment phase and împrovement in clinical symptoms over 2 years in the APIPPRA trial by Cope A, Abstr#OP0130 https://t.co/k0SFDHBRE9

#JAKi May decrease #cancers - age, male, #diabetes had more #cancer but NOT associated w drug prescribed AND LESS #malignancy & LESS #CVE in JAKi vs csDMARDs in huge admin database. Diff from other results OP0140 @RheumNow #EULAR2023 EFFECTIVE Rx of RA LOWERS CVE & cancer w JAKi! https://t.co/oQ3QeUZz3E